FDA Compliance Experts Advise Against Treating Minor Changes As ‘Planned Deviations’
It’s all about change control and risk management, FDA compliance experts tell rapt audience at PDA/FDA conference when confronted with the common practice of planning deviations so that production won’t falter.
You may also be interested in...
Just as they did during the heparin crisis a decade ago, pharmaceutical companies must coordinate on coronavirus, Rx-360 CEO says.
As coronavirus spreads into China’s manufacturing region, quarantines and travel restrictions challenge international flow of pharmaceuticals, ingredients and personnel.
Final gene therapy IND CMC guidance clarifies expectations on process evolution, distinguishing drug substances from products, cGMP oversight and more.